You may have heard on the news that from June 2025, GPs will be able to prescribe the weight loss medication Mounjaro (Tirzepatide). What the news may not have explained completely is that the prescribing rules for GPs around this medication are very stringent indeed, so much so that very few patients will qualify, at least in first few years.
The criteria are:
BMI over 40 or 37.5 for people from minority ethnic backgrounds
and at least 4 of the following:
Hypertension (high blood pressure)
Type 2 Diabetes
Dyslipidaemia (Dyslipidaemia is a broad term describing a number of conditions, including hypercholesterolaemia, hyperlipidaemia and mixed dyslipidaemia, in which disturbances in fat metabolism lead to changes in the concentrations of lipids in the blood.)
Established cardiovascular disease (Cardiovascular disease - NHS)
Diagnosed sleep apnoea
Patients that do qualify will be required to be referred to and engage with behavioural support over a long period of time and will be monitored regularly at the practice for weight loss and general health and well-being, with specific weight loss targets in the first 6 months.
Please could we ask you not to contact the practice regarding being prescribed this medication as it is extremely unlikely that you will qualify given the very strict rules that have been applied. We will contact any patients that falls within the prescribing criteria.